Journey Medical Corp. (DERM)

In October 2025, Journey Medical presented Emrosi Phase 3 clinical trial data at the Fall Clinical Dermatology Conference and participated in investor conferences. In August 2025, the management team rang the Nasdaq Stock Market closing bell to celebrate its four-year anniversary and the commercial launch of Emrosi. The company reported its Q2 2025 financial results in August, noting a quarterly loss of $0.16 per share, which missed estimates, but revenues of $15.01 million surpassed estimates, with Emrosi's launch contributing significantly to revenue. In March 2025, Journey Medical reported its full-year 2024 financial results, meeting all financial guidance and highlighting the FDA approval of Emrosi and its initial distribution, and announced the publication of Emrosi's Phase 3 clinical trial results in JAMA Dermatology. Earlier in April 2024, Journey Medical Corporation appointed Joseph Benesch as Chief Financial Officer.

There is an indication of demand seasonality for Journey Medical Corp.'s products. Revenue from products like Qbrexza and Accutane can be affected by seasonality and insurance deductible resets, and the summer months are generally considered a softer dermatology season. However, the recent launch of Emrosi demonstrated strong traction even during this typically slower period.

Journey Medical Corp. is a commercial-stage pharmaceutical company focused on developing and commercializing innovative dermatology products in the United States. The company specializes in acquiring and commercializing prescription pharmaceutical products for various dermatological conditions, offering a range of branded and generic products to treat common skin ailments like acne, rosacea, and hyperhidrosis. Key products include Qbrexza, Accutane, Amzeeq, Ximino, Zilxi, Exelderm, Luxamend, and Emrosi.

Journey Medical Corp. primarily focuses its commercial efforts on the United States market and its corporate headquarters are located in Scottsdale, Arizona.

Information specifically detailing Journey Medical Corp.'s brand reputation or events that have significantly impacted it in the past year is not readily available. The company's public communications primarily focus on product development, clinical trial results, financial performance, and corporate milestones.

Journey Medical Corp. has a diverse ownership structure, with institutional shareholders owning approximately 26.64%, insiders holding 34.64%, and retail investors accounting for 38.72%. Fortress Biotech Inc. is the largest individual shareholder, owning 16.86% of the company. Other major institutional shareholders include Tang Capital Management LLC, Wasatch Advisors LP, Vanguard Group Inc, and BlackRock, Inc. Claude Maraoui, President and CEO, is also a significant insider owner.